U.S. Markets close in 1 hr 6 mins

IntelliPharmaCeutics International Inc. (IPCI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.38-1.12 (-44.80%)
As of 2:52PM EDT. Market open.
People also watch
CPRXIDRAAPRIACRXBLRX

IntelliPharmaCeutics International Inc.

30 Worcester Road
Toronto, ON M9W 5X2
Canada
416-798-3001
http://www.intellipharmaceutics.com

SectorHealthcare
IndustryDrug Delivery
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Dr. Isa Odidi Ph.D., MBACo-Founder, Chairman, Chief Exec. Officer and Chief Scientific Officer694.49kN/A59
Dr. Amina Odidi Ph.D.Pres, Chief Operating Officer, Co-Chief Scientific Officer and Director694.49kN/A57
Mr. Domenic Della PennaChief Financial Officer352.52kN/AN/A
Mr. Michael CampbellGen. Counsel & Corp. Sec.N/AN/AN/A
Dr. Patrick N. Yat Ph.D.VP of Pharmaceutical Analysis & ChemistryN/AN/A59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. It also develops Rexista Oxycodone, an abuse and alcohol-deterrent controlled-release oral formulation for the relief of pain; Regabatin XR and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; and Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease. In addition, the company offers Glucophage XR, an oral antihyperglycemia drug to treat type 2 diabetes; Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder. Further, it provides Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Corporate Governance

IntelliPharmaCeutics International Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.